AP-31969 is under clinical development by Acesion Pharma and currently in Phase I for Atrial Fibrillation. According to GlobalData, Phase I drugs for Atrial Fibrillation have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AP-31969’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AP-31969 overview

AP-31969 is under development for the treatment of atrial fibrillation. The drug candidate is administered through oral route as tablets and acts by targeting small-conductance calcium-activated potassium (SK) channels.

Acesion Pharma overview

Acesion Pharma is a biotech company that develops medicinal products for the treatment of atrial fibrillation. The company offers development and production of drugs for the treatment of atrial fibrillation, and other cardiac arrhythmias. It also offers development of SK channel inhibitors for the acute treatment of atrial fibrillation. The company develops chronic drug therapy aimed to maintain sinus rhythm and prevent recurrence of atrial fibrillation. It offers drugs for the maintenance of sinus rhythm that relieves atrial fibrillation burden for patients. Acesion Pharma is headquartered in Copenhagen, Denmark.

For a complete picture of AP-31969’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.